Mandate

Vinge acted as local counsel in relation to the sale of Phadia, the biotechnology company, for SEK 22 billion

May 20, 2011

Cinven has entered into an agreement with Thermo Fisher Scientific to sell the Uppsala based biotechnology company, Phadia Group, for SEK 22 billion. Phardia is a spin-off from the former Pharmacia and enjoys a leading position within allergy testing.

Vinge acted as local counsel advising on Swedish legal issues for Cinven/Freshfields. Vinge's team consisted of partner Christina Kokko and associates Joacim Rydergård, Jonas Bergström, Alex Miller and Albert Wållgren.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025